Management costs of chest and CNS-related adverse events associated with the treatment of acute migraine attacks with oral triptans;Costes del manejo clínico de los efectos adversos torácicos y del sistema nervioso central asociados al tratamiento de las crisis agudas de migraña con triptanes orales

Neurologia

Volumn 20, Issue 6, 2005, Pages 290-298

  Slof, John ^a   Badia, X ^b   Lainez J M ^c   Galvan J ^d   Heras, J ^d  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b Health Outcomes Research Europe   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d Almirall Prodesfarma ^*  (Spain)

Author keywords

Adverse event; Costs; Iatrogenic cost factor; Migraine; Triptan

Indexed keywords

ALMOTRIPTAN; ELETRIPTAN; ZOLMITRIPTAN;

ARTICLE; BEHAVIOR; CENTRAL NERVOUS SYSTEM DISEASE; CONSULTATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; EMERGENCY WARD; HEALTH CARE COST; HOSPITAL DEPARTMENT; HUMAN; INCIDENCE; LUNG DISEASE; MIGRAINE; SPAIN;

CENTRAL NERVOUS SYSTEM DISEASES; CHEST PAIN; COST CONTROL; COST-BENEFIT ANALYSIS; DECISION MAKING; HEALTH CARE COSTS; HUMANS; IATROGENIC DISEASE; INDOLES; MIGRAINE DISORDERS; SEROTONIN AGONISTS;

EID: 23644432523     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Ferrari MD. Migraine. Lancet 1998;351:1043-51.
2. Solomon S, Cappa KG, Smith CR. Common migraine: criteria for diagnosis. Headache 1988;28:124-9.
3. Breslau N, Rasmussen BK. The impact of migraine: epidemiology, risk factors and co-morbidities. Neurology 2001;56(6 Suppl. 1):S4-12.
4. Launer LJ, Terwindt GM, Ferrari MD. The prevalence and characteristics of migraine in a population based cohort: the GEM study. Neurology 1999;53:537-42.
5. Stewart WF, Lipton RB, Liberman J. Variation in migraine prevalence by race. Neurology 1996;47:52-9.
6. Van Roijen L, Essink-Bot ML, Koopmanschap MA, Michel BC, Rutten FF. Societal perspective on the burden of migraine in The Netherlands. Pharmacoeconomics 1995;7:170-9.
7. Lainez JM, Vioque J, Hernández I, Titus F. Prevalence of migraine in Spain. An assessment of the questionnaires validity by clinical interview. En: Olesen J, editor. Headache classification and epidemiology. New York: Raven Press Ltd., 1994; p. 221-5.
8. Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache 2002; 42(Suppl. 1):3-9.
9. Freitag FG, Diamond S, Diamond ML, Urban GJ, Pepper BJ. The new treatments in migraine: first year clinical experience. Headache-Q 2000;11:33-6.
10. Winner P, Ricalde O, Le Force B, Saper J, Margul B. A double-blind study of subcutaneous dihydroergotamine vs subcutaneos sumatriptan in the treatment of acute migraine. Arch Neurol 1996;53:180-4.
11. Touchon J, Bertin L, Pilgrim AJ, Ashford E, Bes A. A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in acute treatment of migraine. Neurology 1996;47: 361-5.
12. Maassen Van Den Brink A, Reekers M, Bax WA, Ferrari MD, Saxena PR. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998;98:25-30.
13. Dodick DW. Triptans and chest symptoms: the role of pulmonary vasoconstriction. Cephalalgia 2004;24:298-304.
14. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001;358:1668-75.
15. 1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002;22:633-58.
16. Corrección publicada en Cephalalgia 2003;23:71.
17. Mannix LK, Adelman JU, Goldfarb SD, von Seggern RL, Kozma CM. Almotriptan versus sumatriptan in migraine treatment: direct medical costs of managing adverse chest symptoms. Am J Manag Care 2002;8(3 Suppl.):S94-S101.
18. SOIKOŚ. Barcelona: SOIKOS Centro de Estudios en Economía de Salud y Politica Social, 2003.
19. IMS. Health Therapy Area Sales Report 2002.
20. Ottervanger JP, Valkenburg HA, Grobbee DE, Stricker BH. Characteristics and determinants of sumatriptan-associated chest pain. Arch Neurol 1997;54:1387-92.
21. Young WB, Mannix L, Adelman JU, Shechter AL. Cardiac risk factors and the use of triptans: a survey study. Headache 2000; 40:587-91.
22. Welch KM, Mathew NT, Stone P, Rosamond W, Saiers J, Gutterman D. Tolerability of sumatriptan: clinical trials and post-marketing experience. Cephalalgia 2000;20:687-95.
23. Corrección publicada en Cephalalgia 2001;21:164-5.
24. Wang JT, Barr CE, Goldfarb SD. Impact of chest pain on cost of migraine treatment with almotriptan and sumatriptan. Headache 2002;42(Suppl. 1):38-43.
25. Wang JT, Barr CE, Torigoe Y, Wang E, Rowland CR, Goldfarb SD. Cost savings in migraine associated with less chest pain on new triptan therapy. Am J Manag Care 2002;8(Suppl. 3):S102-7.
26. Tfelt-Hansen P. Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat. Cephalalgia 1998;18:532-8.
27. Tfelt-Hansen P, de Vries P, Saxena PR. A comparative review of pharmacology, pharmacokinetics and efficacy of triptans in migraine. Drugs 2000;6:1259-87.
28. Belsey J. Reconciling effectiveness and tolerability in oral triptan therapy: a quantitative approach to decision making in migraine management. J Clin Res 2001;4:105-25.
29. Gawel MJ, Worthington I, Maggisano A. Progress in clinical neurosciences: a systematic review of the use of triptans in acute migraine. Can J Neurol Sci 2001;28:30-41.